Salarius Pharmaceuticals Stock Plummets to 52-Week Low of $4.23

Salarius Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 4.23 on September 18, 2025. This marks a notable decline in the stock's performance, especially when considering its 52-week high of USD 108.
Over the past year, Salarius Pharmaceuticals has shown a performance increase of 36.69%, which stands in contrast to the S&P 500's performance of 17.14%. Despite this year-over-year growth, the recent drop to a 52-week low highlights the volatility and challenges faced by the company within the miscellaneous industry.

With a market capitalization of USD 2 million, Salarius Pharmaceuticals operates in a competitive landscape. The company's financial metrics reveal a loss-making status, as indicated by the absence of a price-to-earnings ratio. Additionally, the company has a debt-to-equity ratio of 0.79 and an impressive return on equity of 510.34%. However, the price-to-book ratio stands at -2.37, reflecting potential concerns regarding asset valuation.

As the company navigates these financial dynamics, the recent low price may prompt further scrutiny of its market position and operational strategies.